[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-252987-105":53,"doc-detail-252987-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","gcp-inspection-report-procedure-reporting-gcp-inspections-requested-chmp-gcp-inspection-report","GCP Inspection Report - Procedure Reporting GCP Inspections Requested - CHMP GCP Inspection Report","","GCP Inspection Report template for documenting a Good Clinical Practice inspection at a specified site, issued on behalf of the European Medicines Agency. The report captures administrative information, inspection background, and grading of findings, then details operational resources including organization, personnel, facilities, equipment, and computer systems. It outlines trial administrative aspects, trial master file expectations, clinical conduct, sponsor/CRO trial management, safety reporting, investigational medicinal product handling, clinical data management, source data review, monitoring, diagnostics, sample and laboratory activities, bioanalysis, pharmacokinetic and statistical analysis, and the required report deliverables.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/gcp-inspection-report-procedure-reporting-gcp-inspections-requested-chmp-gcp-inspection-report/252987/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/gcp-inspection-report-procedure-reporting-gcp-inspections-requested-chmp-gcp-inspection-report/252987.png","ImageObject",442,249,{"name":88,"@type":89},"\tCallum ","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-27","2026-09-13",true,{"@type":98,"interactionType":99,"userInteractionCount":35},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What administrative details are required at the start of the GCP inspection report?","Question",{"text":108,"@type":109},"The report requires inspector identity and contact information, the inspection report date, and information about responses and their evaluation dates as referenced by addenda.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Which topics are covered under operational resources during the inspection documentation?",{"text":113,"@type":109},"It includes organization, personnel, qualifications and training, facilities, equipment, and computer systems.",{"name":115,"@type":106,"acceptedAnswer":116},"How does the report structure address trial files, safety, and data processes?",{"text":117,"@type":109},"It specifies Trial Master File requirements, outlines safety reporting, and covers clinical data management and source data review/verification, followed by monitoring and related activities.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},252987,1790238124,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":35,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":141},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","GCP Inspection Report XXX at XXX site  \nOn behalf of the European Medicines Agency  \nXXX  \nInspector in charge of this inspection report  \nName:  \nPosition:  \nAddress:  \nTel:  \nE-mail:  \nXXX XXX XXX  \nInspection report date: DD-MM-YYYY  \nResponses to inspection report: Dated as per Addendum 1  \nEvaluation of inspection responses: Dated as per Addendum 2  \nThis inspection report may only be reproduced in its entirety and must not be circulated or published without the European Medicines Agency’s consent, nor may any additions be made to the report.  \nTable of contents  \n1. Administrative information ................................................................................................ 5  \n2. Background and general information ................................................................................. 6  \n2.1. Reason and cause for the inspection .................................................................................... 6  \n2.2. Reference texts ................................................................................................................ 6  \n2.3. Grading of findings ........................................................................................................... 6  \n2.4. List of persons involved in the trial and contacted during the inspection ................................... 7  \n3. Operational resources ........................................................................................................ 8  \n3.1. Organisation .................................................................................................................... 8  \n3.2. Personnel ........................................................................................................................ 8  \n3.3. Qualifications and training ................................................................................................. 8  \n3.4. Facilities ......................................................................................................................... 8  \n3.5. Equipment....................................................................................................................... 8  \n3.6. Computer systems ............................................................................................................ 8  \n4. Administrative aspects of the trial ..................................................................................... 8  \n4.1. National competent authority ............................................................................................. 8  \n4.2. Independent research ethics committee (IEC) ...................................................................... 8  \n4.3. Other committees, any other validation or authorisations required........................................... 8  \n4.4. Contract(s) and agreement(s) ............................................................................................ 8  \n4.5. Insurance ........................................................................................................................ 8  \n5. Trial master file.................................................................................................................. 9  \n5.1. Production, version control and content of essential documents ............................................... 9  \n5.2. Completeness, availability, content and structure of TMF/ISF .................................................. 9  \n6. Clinical conduct of the trial ................................................................................................ 9  \n7. Management of the trial by sponsor/CRO .......................................................................... 9  \n8. Safety reporting ................................................................................................................. 9  \n9. Investigational medicinal product(s) (IMPs)/pharmacy .................................................... 9  \n10. Clinical data mana","cbCaidyLWp7iGYyd","https://ap.wps.com/l/cbCaidyLWp7iGYyd","pdf",376263,26,"English","# Administrative information\n# Background and general information\n## Reason and cause for the inspection\n## Reference texts\n## Grading of findings\n## List of persons involved in the trial and contacted during the inspection\n# Operational resources\n## Organisation\n## Personnel\n## Qualifications and training\n## Facilities\n## Equipment\n## Computer systems\n# Administrative aspects of the trial\n## National competent authority\n## Independent research ethics committee (IEC)\n## Other committees, any other validation or authorisations required\n## Contract(s) and agreement(s)\n## Insurance\n# Trial master file\n## Production, version control and content of essential documents\n## Completeness, availability, content and structure of TMF/ISF\n# Clinical conduct of the trial\n# Management of the trial by sponsor/CRO\n# Safety reporting\n# Investigational medicinal product(s) (IMPs)/pharmacy\n# Clinical data management\n# Source data review/verification\n# Clinical trial monitoring\n# Instrument-based diagnostics/ examinations\n# Clinical sample management\n## Clinical samples (at investigator site)\n## Clinical samples (at laboratory or analytical site)\n# Laboratory\n# Bioanalysis (PK) laboratory\n## Methods used\n## Method validation and report\n## Results\n# Pharmacokinetic analysis\n# Statistical analysis\n# Reports\n## Clinical study report","[{\"question\":\"What administrative details are required at the start of the GCP inspection report?\",\"answer\":\"The report requires inspector identity and contact information, the inspection report date, and information about responses and their evaluation dates as referenced by addenda.\"},{\"question\":\"Which topics are covered under operational resources during the inspection documentation?\",\"answer\":\"It includes organization, personnel, qualifications and training, facilities, equipment, and computer systems.\"},{\"question\":\"How does the report structure address trial files, safety, and data processes?\",\"answer\":\"It specifies Trial Master File requirements, outlines safety reporting, and covers clinical data management and source data review/verification, followed by monitoring and related activities.\"}]","GCP Inspection Report - Procedure Reporting GCP Inspections Requested - CHMP GCP Inspection Report | PDF",1789263684,9]